-transparent.png){kind=logo}
Fifteen patients with the unequivocal diagnosis of amyotrophic lateral sclerosis (ALS) completed a 1-year randomized double-blind placebo-controlled trial of L-threonine (2 g daily). During the study, patients in the placebo group showed a decline in functional status consistent with the natural history of ALS, which was not statistically different from outcome in the patients in the L-threonine group.
Related Publications
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
February 1986,
Neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
August 2023,
Nature communications,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
December 1989,
Neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
October 2019,
Journal of neurology, neurosurgery, and psychiatry,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
August 1984,
Neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
June 1995,
Archives of neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
January 2012,
PloS one,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
January 1998,
Archives of neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
January 2023,
European journal of neurology,
O Blin, and
J Pouget, and
G Aubrespy, and
C Guelton, and
A Crevat, and
G Serratrice
August 1984,
Neurology,
